For the first time in U.S. history, a psychedelic drug may be on the verge of FDA approval as a prescription treatment for a psychiatric condition. And the regulatory timeline has compressed significantly in the past two months.
On April 18, 2026, President Trump signed an executive order directing federal agencies to accelerate the research, review, and approval of psychedelic drugs as treatments for serious mental health conditions. Just six days later, FDA Commissioner Marty Makary issued National Priority Vouchers to three psychedelic therapy programs — vouchers that can compress the FDA’s standard 10-to-12-month drug application review to one to two months.
The most advanced of the three is Compass Pathways’ synthetic psilocybin, called COMP360, for treatment-resistant depression (TRD). The company is already rolling out NDA submission, with sections already submitted and the final NDA on track for Q4 2026. If all goes as planned, the FDA could issue its first approval decision for a classic psychedelic therapy by late 2026 or early 2027.
Why This Matters
Treatment-resistant depression — defined as depression that has not responded to at least two adequate courses of antidepressant treatment — affects an estimated 2 to 3 million Americans. For this population, existing options are limited and often inadequate. The approved medications for TRD include esketamine (Spravato) and lithium augmentation, but neither works for everyone, and both have significant limitations.
Psilocybin therapy, as studied in clinical trials, works differently from every other antidepressant currently available. Instead of a daily pill, clinical participants received one to three supervised dosing sessions. Response occurred as early as the day after treatment. Effects have lasted at least six months with just one or two doses in the trial data.
If COMP360 is approved, it would represent the first genuinely new mechanism of action in psychiatric pharmacology since ketamine and the first drug in its class to be approved for a psychiatric indication.
What We Know So Far
Compass Pathways achieved two consecutive positive Phase 3 trial results:
COMP005 (June 2025): The first Phase 3 trial for COMP360 in TRD hit its primary endpoint with high statistical significance. This was the first positive Phase 3 result for any classic psychedelic in any psychiatric indication in U.S. history.
COMP006 (February 2026): The second Phase 3 trial confirmed the positive results, hitting its primary endpoint with high statistical significance. The company expects 26-week follow-up data from COMP006 in early Q3 2026.
According to Compass Pathways’ SEC filings, the FDA granted the company permission for rolling NDA submission and review based on the strength of the positive Phase 3 data. Sections of the NDA have already been submitted. The White House executive order also directed the DEA to initiate and complete a review of psilocybin’s scheduling, “so that rescheduling may proceed as quickly as possible” once Phase 3 is complete. COMP360 is currently a Schedule I controlled substance, which it would need to be rescheduled from before commercial distribution can begin.
The Three Psychedelic Programs in Priority Review
According to Foley & Lardner’s analysis of the FDA’s April 24 announcement:
- Compass Pathways — COMP360 (synthetic psilocybin) for treatment-resistant depression. Most advanced; rolling NDA underway.
- Usona Institute — psilocybin for major depressive disorder. Less advanced in the NDA process; targets a broader depression indication.
- Transcend Therapeutics — TSND-201 (methylone, an MDMA-like compound) for PTSD. Subject to acquisition by Otsuka Pharmaceutical Co.
The National Priority Voucher applies to all three programs and would compress the FDA’s review to one to two months once the full application is submitted.
What the Evidence Shows — and What It Does Not
MedicalDaily Evidence Check
- Study type: Phase 3 randomized clinical trials (COMP005 and COMP006)
- Indication: Treatment-resistant depression (failed at least 2 prior antidepressant courses)
- Participants: More than 1,000 participants enrolled across the two Phase 3 trials
- Results: Both trials hit primary endpoints with high statistical significance
- What it found: Significant reduction in depression symptoms versus placebo; response as early as the day after dosing; sustained effects measured at least 6 months with 1–2 doses
- What it did not fully address: Long-term safety beyond 6 months with repeated administration; effectiveness outside of controlled, therapist-supervised clinical settings; performance in all TRD subpopulations
- Regulatory status: Rolling NDA underway; not yet approved; COMP360 remains Schedule I
Psilocybin therapy, as studied, requires a structured clinical setting with trained therapists, preparation sessions before dosing, and integration sessions after. The approval, if granted, would be under a Risk Evaluation and Mitigation Strategy (REMS) program — meaning it would only be available through certified treatment centers, not as a take-home prescription.
What Doctors and Experts Say
Kabir Nath, CEO of Compass Pathways, called the FDA’s National Priority Voucher “a clear validation of both the urgent unmet need facing millions of people living with treatment-resistant depression and the innovative science of COMP360.” The company has said it expects any center currently delivering esketamine (Spravato) to be able to deliver COMP360, a network that could enable meaningful early access if approval comes through.
Mental health policy experts at the Petrie-Flom Center at Harvard note that the executive order represents a significant federal policy shift and that the voucher mechanism is genuinely novel, but also that it does not, by itself, approve any drug or guarantee an outcome.
Who Would Be Eligible?
COMP360, if approved, would be indicated for adults with treatment-resistant depression — meaning those who have not responded to at least two adequate antidepressant courses. The REMS requirements for supervised clinical administration mean it would not be a primary-care prescription. It would be dispensed only in certified treatment centers by trained clinicians and supervised therapists.
What You Can Do Now
- COMP360 is not yet approved. Do not seek out psilocybin therapy through non-medical sources — including “retreat” programs, unregulated therapists, or online sources — in anticipation of approval. These settings carry legal and health risks.
- If you or a family member has treatment-resistant depression, discuss current FDA-approved options — including esketamine (Spravato) — with a psychiatrist while COMP360’s approval process unfolds.
- Follow the FDA’s Drug Approval Package database and Compass Pathways’ investor communications for Q4 2026 NDA submission announcements.
- Oregon and Colorado have established legal frameworks for supervised psilocybin therapy at the state level, separate from FDA approval. These programs are active and legal in those states, though not covered by insurance.
Cost and Access: What Patients Should Know
Insurance coverage for an approved COMP360 would require separate decisions by CMS, commercial insurers, and pharmacy benefit managers. Vicente LLP’s analysis notes that federal approval does not guarantee insurance coverage, and reimbursement pathways remain an open question. The structured, therapist-supervised nature of treatment — which is not a brief office visit but multiple hours — adds complexity to how coverage would be structured.
What Happens Next
Compass Pathways expects to complete the rolling NDA submission in Q4 2026. Once the full NDA is submitted, the National Priority Voucher triggers the one-to-two-month review timeline. The FDA will also need to develop REMS requirements for supervised administration. In parallel, the DEA must evaluate rescheduling psilocybin from Schedule I. This process could add additional time between approval and commercial availability. MedicalDaily will report on NDA submission, FDA advisory committee dates, and approval decisions as they occur.
The Bottom Line
The regulatory path for the first FDA-approved psychedelic therapy is more advanced than at any point in history. Two consecutive positive Phase 3 trials, a presidential executive order, and a priority review voucher that compresses the review timeline to one to two months all point toward a late 2026 or early 2027 decision. For the 2 to 3 million Americans with treatment-resistant depression, this is a development worth following closely, while continuing to work with a psychiatrist on currently available options in the meantime.
